NCT01766076View on ClinicalTrials.gov

Atorvastatin for HAART Suboptimal Responders

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Acquired Immune Deficiency Syndrome Virus
Interventions
OTHER

atorvastatin, Lipitor®

PBMC collected for immune activation assays using flowcytometry

DRUG

Placebo

PBMC collected for immune activation assays using flowcytometry

All Listed Sponsors
collaborator

Vaccine and Gene Therapy Institute, Florida

OTHER

lead

Makerere University

OTHER

NCT01766076 - Atorvastatin for HAART Suboptimal Responders | Biotech Hunter | Biotech Hunter